Newsroom | 85084 results

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, applauds recent comments made by Dr. Martin Makary, Commissioner of the U.S. FDA relating to the importance of accelerating and prioritizing research on the clinical benefits of psychedelic therapeutics. “It is gratifying that th...

CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day...

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research manuscript in Nature Communications: “Optimized AAV capsids for basal ganglia diseases show robust potency and distribution.” The study, led by Latus founder Beverly Davidson, Ph.D., details the discovery of a novel adeno-associated virus (AAV) capsid variant - AAV-DB-3 - that is poised to address the long-...

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug (“veli”), an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmun...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it will present results from the Phase 3 SURPASS-ET clinical trial in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chic...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa....

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial officer to pursue other opportunities. Richie Jain, who previously served as Schrödinger’s senior vice president, strategic finance and head of corporate and business development, will succeed Geoffrey Porges as chief financial officer. Dr. Porges will serve as an advisor to the company through June 6...

CAMBRIDGE, England--(BUSINESS WIRE)--Shift Bioscience (Shift), a biotech company using an AI powered virtual cell to fight age-driven diseases, today announced the appointments of Lord David Prior as Chair of the Board and Sir Tony Kouzarides as Scientific Advisor. Bringing significant industry expertise and leadership, Tony and David will provide crucial support to advance Shift’s therapeutic pipeline, helping to foster new industry partnerships and broaden awareness of the Company’s long-term...

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial availability of ZEVTERA® (ceftobiprole medocaril sodium for injection), the newest addition to the Company’s growing antibiotic portfolio. ZEVTERA is the only U.S. Food and Drug Administration (FDA) approved advanced-generation cephalosporin indicated to treat adult patients with Staphylococcus aureus bloodstream infection (bacteremi...